The ROS-1 NSCLC current market is mainly dominated by tyrosine kinase inhibitors such as XALKORI at present and is anticipated to be dominated by Repotrectinib, Taletrectinib, and NVL-520 by 2034.

The drug is under Priority Review by the U.S. Food and Drug Administration (FDA) and has a Prescription Drug User Fee Act (PDUFA) date of June 23, 2025 NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc.

NEW YORK--(BUSINESS WIRE)--AnHeart Therapeutics (“AnHeart”), a clinical-stage global biopharmaceutical company committed to developing novel cancer therapies, today announced that the first patient ...

NEW YORK--(BUSINESS WIRE)-- Nuvation Bio Inc. (NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that Japan’s Ministry of Health ...

Zidesamtinib is an investigational, novel brain-penetrant ROS1-selective inhibitor created with the aim to overcome limitations observed with currently available ROS1 inhibitors. Zidesamtinib is ...

Application based on data from the registrational TRIDENT-1 and CARE trials showing robust responses and durable activity in these patient populations If approved, repotrectinib will offer a potential ...

While three Big Pharma companies have yet to successfully crack the ROS1 lung cancer market, young biotech Nuvalent believes competitive pivotal data from its investigational drug are paving the way ...

An expert explained what ROS1-positive non-small cell lung cancer is and why it is important to identify mutations like ROS1 through genetic sequencing. ROS1-positive non-small cell lung cancer, a ...

Sustained durability of responses demonstrated in both TRUST-I and TRUST-II with additional follow-up time TKI-naïve patients in TRUST-I achieved a median progression-free survival of 44.6 months; ...